Transcriptional programming drives Ibrutinib-resistance evolution in mantlecell lymphoma.

Zhao, Xiaohong et al.

Ibrutinib, a bruton's tyrosine kinase (BTK) inhibitor, provokes robust clinical responses in aggressive mantle cell lymphoma (MCL), yet many patients relapse with lethal Ibrutinib-resistant (IR) disease. Here, using genomic, chemical proteomic, and drug screen profiling, we report that enhancer remodeling-mediated transcriptional activation and adaptive signaling changes drive the aggressive phenotypes of IR. Accordingly, IR MCL cells are vulnerable to inhibitors of the transcriptional machinery and especially so to inhibitors of cyclin-dependent kinase 9 (CDK9), the catalytic subunit of the positive transcription elongation factor b (P-TEFb) of RNA polymerase II (RNAPII). Further, CDK9 inhibition disables reprogrammed signaling circuits and prevents the emergence of IR in MCL. Finally, and importantly, we find that a robust and facile ex vivo image-based functional drug screening platform can predict clinical therapeutic responses of IR MCL and identify vulnerabilities that can be targeted to disable the evolution of IR.


Share this article

March, 2021


Products used in this publication

  • ChIP-seq Grade
    Pol II monoclonal antibody
  • some alt
    1.5 ml Bioruptor® Plus TPX microtubes
  • some alt
    1.5 ml Bioruptor® Plus TPX microtubes
  • Bioruptor Pico
    Picoruptor 2 sonication device


  • EpiPlant 2024
    Clermont-Ferrand, France
    Jul 10-Jul 12, 2024


       Site map   |   Contact us   |   Conditions of sales   |   Conditions of purchase   |   Privacy policy